Chitin – and Chitosan‐Based Scaffolds

Bulbake, Upendra; Doppalapudi, Sindhu; Khan, Wahid

doi:10.1002/9781119364849.ch11

Cited by 3 publications

(2 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, of the nanomedicine drugs approved by the Federal Drug Administration (FDA), lipid-based systems constitute the vast majority and are the leading material in future drug development systems. 14,15 In addition, lipids exist in numerous complex structures within the ECM including exosomes and several other lipidbased extracellular vesicles, 16 which have been implicated in ECM modulation within several physiological and pathological contexts. 17 To prevent protein adsorption onto nanoparticles, poly(ethylene glycol) (PEG) has been incorporated onto the surfaces of nanoparticles via the inclusion of a lipid that is covalently linked to PEG, effectively "cloaking" the particle to evade protein interactions, thus prolonging their circulation lifetime.…”

Section: Introductionmentioning

confidence: 99%

The structural fate of lipid nanoparticles in the extracellular matrix

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The structural fate of lipid nanoparticles in the extracellular matrix

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Advax is a novel adjuvant that has recently entered human trials. 138 One group has shown that the formulation of a TB antigen with Advax provides significant protection in the lungs of M. tuberculosisinfected mice. The protection was associated with the generation of antigen-specific multifunctional CD4+ T-cells, and addition of the TLR9 agonist, CpG, further improved both the immunogenicity and protective efficacy of the vaccine.…”

Section: Polymeric Biomaterialsmentioning

confidence: 99%

Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases

Yenkoidiok-Douti

Jewell

2020

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Despite the success of vaccines in preventing many infectious diseases, effective vaccines against pathogens with ongoing challenges -such as HIV, malaria, and tuberculosis -remain unavailable. The emergence of new pathogen variants, the continued prevalence of existing pathogens, and the resurgence of yet other infectious agents motivate the need for new, interdisciplinary approaches to direct immune responses. Many current and candidate vaccines, for example, are poorly immunogenic, provide only transient protection, or create risks of regaining pathogenicity in certain immune-compromised conditions. Recent advances in biomaterials research are creating new potential to overcome these challenges through improved formulation, delivery, and control of immune signaling. At the same time, many of these materials systems -such as polymers, lipids, and self-assembly technologies -may achieve this goal while maintaining favorable safety profiles. This review highlights ways in which biomaterials can advance existing vaccines to safer, more efficacious technologies, and support new vaccines for pathogens that do not yet have vaccines. Biomaterials that have not yet been applied to vaccines for infectious disease are also discussed, and their potential in this area is highlighted

show abstract